In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

Triple-negative breast cancer patients on Keytruda had significantly improved response rates compared to chemo, despite taking one tenth the standard dose.

Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.

NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac, a deal that was announced in June.

Under the deal, which was first announced in September, Novartis will pay Arrowhead $200 million upfront. Arrowhead is eligible for additional payments of up to $2 billion tied to development, ...

In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

In this tough-to-treat cancer type, more patients receiving anzu-cel saw their tumors shrink and had durable responses than what's been seen with other therapies.

The firm will launch a Phase I trial in healthy volunteers in the Netherlands to establish safety and proof-of-target engagement.

As Novartis moves ahead plans to expand Pluvicto's use based on the PSMAddition trial, experts urge for greater use of ...

NEW YORK – Galapagos on Tuesday said that after a strategic review it has decided to wind down its cell therapy business, which includes several CAR T-cell therapies in development for blood cancers ...